Sunshine Biopharma, Inc. (SBFM)
1.12
-0.05
(-4.27%)
USD |
NASDAQ |
Sep 03, 16:00
1.13
+0.01
(+0.89%)
After-Hours: 20:00
Sunshine Biopharma Net Income (Quarterly) : -1.564M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.564M |
| March 31, 2026 | -1.244M |
| December 31, 2025 | -2.141M |
| September 30, 2025 | -0.8838M |
| June 30, 2025 | -1.771M |
| March 31, 2025 | -1.180M |
| December 31, 2024 | -2.158M |
| September 30, 2024 | -1.198M |
| June 30, 2024 | -0.4943M |
| March 31, 2024 | -1.284M |
| December 31, 2023 | -1.25M |
| September 30, 2023 | -0.6515M |
| June 30, 2023 | -0.9021M |
| March 31, 2023 | -1.702M |
| December 31, 2022 | -23.51M |
| September 30, 2022 | -1.457M |
| June 30, 2022 | -0.5389M |
| March 31, 2022 | -1.236M |
| December 31, 2021 | 0.6671M |
| September 30, 2021 | -4.039M |
| June 30, 2021 | -2.879M |
| March 31, 2021 | -6.185M |
| December 31, 2020 | -1.084M |
| September 30, 2020 | -0.6986M |
| June 30, 2020 | -0.9074M |
| Date | Value |
|---|---|
| March 31, 2020 | -0.0943M |
| December 31, 2019 | -0.3966M |
| September 30, 2019 | -0.3502M |
| June 30, 2019 | -0.1308M |
| March 31, 2019 | -0.2004M |
| December 31, 2018 | -0.3293M |
| September 30, 2018 | -0.9128M |
| June 30, 2018 | -0.6497M |
| March 31, 2018 | -0.2656M |
| December 31, 2017 | -0.2115M |
| September 30, 2017 | -0.1476M |
| June 30, 2017 | -0.4854M |
| March 31, 2017 | -0.1957M |
| December 31, 2016 | -1.124M |
| September 30, 2016 | -1.586M |
| June 30, 2016 | -0.4813M |
| March 31, 2016 | -0.3053M |
| December 31, 2015 | -0.6477M |
| September 30, 2015 | -0.2028M |
| June 30, 2015 | -0.5175M |
| March 31, 2015 | -0.2944M |
| December 31, 2014 | -0.3337M |
| September 30, 2014 | -0.2808M |
| June 30, 2014 | -0.8184M |
| March 31, 2014 | -0.5013M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 9.264M |
| Total Expenses (Quarterly) | 10.83M |
| EPS Diluted (Quarterly) | -1.146 |
| Enterprise Value | -10.26M |
| Gross Profit Margin (Quarterly) | 25.35% |
| Profit Margin (Quarterly) | -16.88% |
| Earnings Yield | -913.0% |
| Normalized Earnings Yield | -819.24 |